Table 1 Patient baseline characteristics. Only patients receiving peripheral blood stem cell (PBSC) grafts and with patients receiving ATG or GVHD-prophylaxis other than CsA/MMF/sirolimus or Tac/MTX excluded.
All, n = 77 | MA, n = 34 | NMA, n = 43 | ||||||
|---|---|---|---|---|---|---|---|---|
Age, years median (IQR) | 63 | (55–68) | 58 | (52–64) | 65 | (61–70) | ||
Sex, n (%) | ||||||||
Female | 30 | (39.0) | 15 | (44.1) | 15 | (34.9) | ||
Male | 47 | (61.0) | 19 | (55.9) | 28 | (65.1) | ||
Disease, n (%) | ||||||||
Myelodysplastic syndrome | 40 | (51.9) | 23 | (67.7) | 17 | (39.5) | ||
Acute myeloid leukemia | 24 | (31.2) | 9 | (26.5) | 15 | (34.9) | ||
Lymphoma | 9 | (11.7) | 0 | (0.0) | 9 | (20.9) | ||
Acute lymphoblastic leukemia | 2 | (2.6) | 1 | (2.9) | 1 | (2.3) | ||
Other leukemia | 2 | (2.6) | 1 | (2.9) | 1 | (2.3) | ||
Conditioning, n (%) | ||||||||
Myeloablative | 34 | (44.2) | 34 | (100.0) | 0 | (0.0) | ||
Non-myeloablative | 43 | (55.8) | 0 | (0.0) | 43 | (100.0) | ||
Conditioning regimen, n (%) | ||||||||
FluTreo | 33 | (42.9) | 33 | (97.1) | 0 | (0.0) | ||
FluTreoTBI-2 Gy | 1 | (1.3) | 1 | (2.9) | 0 | (0.0) | ||
FluTBI-2 Gy | 19 | (24.7) | 0 | (0.0) | 19 | (44.2) | ||
FluTBI-3 Gy | 24 | (31.2) | 0 | (0.0) | 24 | (55.8) | ||
Karnofsky Performance Status, n (%) | ||||||||
< 80 | 9 | (11.7) | 5 | (14.7) | 4 | (9.3) | ||
90 | 41 | (53.3) | 16 | (47.1) | 25 | (58.1) | ||
100 | 24 | (31.2) | 13 | (38.2) | 11 | (25.6) | ||
Unknown | 3 | (3.9) | 0 | (0.0) | 3 | (7.0) | ||
Donor age, years median (IQR) | 26 | (22–34) | 27 | (22–36) | 26 | (22–34) | ||
Donor sex, female, n (%) | 28 | (36.4) | 15 | (44.1) | 13 | (30.2) | ||
Female donor/male recipient, n (%) | 10 | (13.0) | 5 | (14.7) | 4 | (9.3) | ||
Recipient/donor relation, n (%) | ||||||||
Unrelated | 69 | (89.6) | 27 | (79.4) | 42 | (97.7) | ||
Sibling | 8 | (10.4) | 7 | (20.6) | 1 | (2.3) | ||
Recipient/donor HLA match, n (%) | ||||||||
10/10 matched, identical unrelated donor | 62 | (80.5) | 26 | (76.5) | 36 | (83.7) | ||
9/10 matched, unrelated donor | 8 | (10.4) | 1 | (2.9) | 7 | (16.3) | ||
Matched, identical sibling | 7 | (9.1) | 7 | (20.6) | 0 | (0.0) | ||
Graft-versus-host-disease prophylaxis, n (%) | ||||||||
CsA + MMF + sirolimus | 43 | (58.8) | 0 | (0.0) | 43 | (100.0) | ||
Tac + MTX | 34 | (44.2) | 34 | (100.0) | 0 | (0.0) | ||
